National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 54476-54477 [2011-22454]
Download as PDF
<![CDATA[
54476
Federal Register / Vol. 76, No. 170 / Thursday, September 1, 2011 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN SUMMARY, BIOLOGICAL AND PHYSICAL MEASURES—Continued
Data collection activity
Focus groups ....................................
Cognitive interviews ..........................
srobinson on DSK4SPTVN1PROD with NOTICES
Total ...........................................
16:16 Aug 31, 2011
Estimated
number of
responses per
respondent
Average
burden hours
per response
Estimated total
annual burden
hours
requested
Community Stakeholders .................
NCS participants ..............................
Members of NCS target population
(not NCS participants).
Health and Social Service Providers
Community Stakeholders .................
NCS participants ..............................
Members of NCS target population
(not NCS participants).
2,000
2,000
2,000
1
1
1
1
1
1
2,000
2,000
2,000
2,000
2,000
500
500
1
1
1
1
1
1
2
2
2,000
2,000
1,000
1,000
...........................................................
113,000
........................
........................
60,000
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information collected; and (4) Ways to
minimize the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attn: NIH Desk Officer, by E-mail to
OIRA_submission@omb.eop.gov, or by
fax to 202–395–6974. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Ms.
Jamelle E. Banks, Public Health Analyst,
Office of Science Policy, Analysis and
Communication, National Institute of
Child Health and Human Development,
31 Center Drive Room 2A18, Bethesda,
Maryland, 20892, or call a non-toll free
number (301) 496–1877 or E-mail your
request, including your address to
banksj@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
VerDate Mar<15>2010
Estimated
number of
respondents
Type of respondent
Jkt 223001
received within 30 days of the date of
this publication.
Dated: August 25, 2011.
Jamelle E. Banks,
Public Health Analyst, Office of Science
Policy, Analysis and Communications,
National Institute of Child Health and Human
Development.
[FR Doc. 2011–22456 Filed 8–31–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Ancillary
Studies to Major Ongoing Clinical Studies:
DCCT/EDIC.
Date: September 30, 2011.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Contact Person: Najma Begum, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 749, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; R24 Seeding.
Date: October 5, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: D.G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Novel Therapies for
NIDDM P01.
Date: October 14, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: D.G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Fellowships in
Digestive Diseases and Nutrition.
Date: October 18, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Kabuki, 1625 Post Street, San
Francisco, CA 94115.
Contact Person: Thomas A. Tatham, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993.
tathamt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 76, No. 170 / Thursday, September 1, 2011 / Notices
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 26, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–22454 Filed 8–31–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
Mrs.
Giselle Hersh, Division of Workplace
FOR FURTHER INFORMATION CONTACT:
VerDate Mar<15>2010
16:16 Aug 31, 2011
Jkt 223001
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires {or set}
strict standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016, (Formerly:
Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150.
Aegis Analytical Laboratories, 345
Hill Ave., Nashville, TN 37210, 615–
255–2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.).
Alere Toxicology Services, 1111
Newton St., Gretna, LA 70053, 504–
361–8989/800–433–3823, (Formerly:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
54477
Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA 23236,
804–378–9130, (Formerly: Kroll
Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll
Scientific Testing Laboratories, Inc.).
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock, AR
72209–7056, 501–202–2783, (Formerly:
Forensic Toxicology Laboratory Baptist
Medical Center).
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
215–674–9310.
ElSohly Laboratories, Inc., 5
Industrial Park Drive, Oxford, MS
38655, 662–236–2609.
Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630.
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919–
572–6900/800–833–3984. (Formerly:
LabCorp Occupational Testing Services,
Inc., CompuChem Laboratories, Inc.;
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group).
Laboratory Corporation of America
Holdings, 1120 Main Street, Southaven,
MS 38671, 866–827–8042/800–233–
6339, (Formerly: LabCorp Occupational
Testing Services, Inc.; MedExpress/
National Laboratory Center).
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS 66219,
913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.).
Maxxam Analytics*, 6740
Campobello Road, Mississauga, ON,
Canada L5N 2L8, 905–817–5700,
(Formerly: Maxxam Analytics Inc.,
NOVAMANN (Ontario), Inc.).
E:\FR\FM\01SEN1.SGM
01SEN1
]]>Agencies
[Federal Register Volume 76, Number 170 (Thursday, September 1, 2011)]
[Notices]
[Pages 54476-54477]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-22454]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; NIDDK Ancillary Studies
to Major Ongoing Clinical Studies: DCCT/EDIC.
Date: September 30, 2011.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Najma Begum, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 749,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; R24 Seeding.
Date: October 5, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: D.G. Patel, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 756,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Novel Therapies for
NIDDM P01.
Date: October 14, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: D.G. Patel, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 756,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Fellowships in Digestive
Diseases and Nutrition.
Date: October 18, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Hotel Kabuki, 1625 Post Street, San Francisco, CA 94115.
Contact Person: Thomas A. Tatham, PhD, Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-3993. tathamt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes,
[[Page 54477]]
Endocrinology and Metabolic Research; 93.848, Digestive Diseases and
Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology
Research, National Institutes of Health, HHS)
Dated: August 26, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-22454 Filed 8-31-11; 8:45 am]
BILLING CODE 4140-01-P
